Abstract
Objective: To investigate the efficacy of neoadjuvant chemotherapy with modified FOLFOX regimen for patients with advanced gastric cancer. Methods: Between September 2006 and September 2008, a total of 80 patients with advanced gastric cancer were divided into neoadjuvant chemotherapy+surgery group (Group A) and surgery alone group (Group B), with 40 patients in each group. In Group A, we administered neoadjuvant chemotherapy with OXA 100mg/m~2 iv d1(2hr), CF 400mg/m~2 iv d1 (2hr), and 5-FU 2 400mg/m~3 civ d1(46hr). After 2 treatment cycles, CT was performed in all patients. Results: In Group A, the clinical efficacy (CR+PR) was 52.5% (21/40); the SD was 37.5% (15/40), and PD was 10.0% (4/40). The overall resectability rate was 92.5% (37/40); and the curative resection rate was 77.5% (31/40); only 7.5% (3/40) had exp.lap. In Group B, the overall resectability rate was 75.0% (30/40); the curative resection rate was 52.5% (21/40); and 22.5% (9/40) had exp.lap. No mortality was observed. No significant differences were found in toxicities between the two groups. Conclusion: Neoadjuvant chemotherapy with modified FOLFOX regimen is safe and effective for patients with advanced gastric cancer and can increase the overall resectability rate and the curative resection rate.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
